PH12021552675A1 - Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer - Google Patents

Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Info

Publication number
PH12021552675A1
PH12021552675A1 PH1/2021/552675A PH12021552675A PH12021552675A1 PH 12021552675 A1 PH12021552675 A1 PH 12021552675A1 PH 12021552675 A PH12021552675 A PH 12021552675A PH 12021552675 A1 PH12021552675 A1 PH 12021552675A1
Authority
PH
Philippines
Prior art keywords
inhibitors
lag
combination
inhibitor
treating cancer
Prior art date
Application number
PH1/2021/552675A
Other languages
English (en)
Inventor
Glenn Kroog
Tasha N Sims
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12021552675A1 publication Critical patent/PH12021552675A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2021/552675A 2019-05-13 2020-05-12 Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer PH12021552675A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847068P 2019-05-13 2019-05-13
PCT/US2020/032515 WO2020232019A1 (en) 2019-05-13 2020-05-12 Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Publications (1)

Publication Number Publication Date
PH12021552675A1 true PH12021552675A1 (en) 2022-07-04

Family

ID=71069936

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552675A PH12021552675A1 (en) 2019-05-13 2020-05-12 Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Country Status (17)

Country Link
US (1) US20220249659A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969040A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532490A (cg-RX-API-DMAC7.html)
KR (1) KR20220007593A (cg-RX-API-DMAC7.html)
CN (2) CN113825527A (cg-RX-API-DMAC7.html)
AU (1) AU2020276242B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021713A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136568A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002966A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192528A1 (cg-RX-API-DMAC7.html)
IL (1) IL287728A (cg-RX-API-DMAC7.html)
MA (1) MA55965A (cg-RX-API-DMAC7.html)
MX (1) MX2021013815A (cg-RX-API-DMAC7.html)
PH (1) PH12021552675A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111262XA (cg-RX-API-DMAC7.html)
WO (1) WO2020232019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107760B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
US20210128710A1 (en) * 2019-11-04 2021-05-06 Inovio Pharmaceuticals, Inc. Combination therapy to treat brain cancer
US20250270321A1 (en) * 2021-02-23 2025-08-28 Regeneron Pharmaceuticals, Inc. Methods of treating lung cancer by administering a pd-1 inhibitor
IL309120A (en) * 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for the treatment of cancer
WO2023019240A2 (en) 2021-08-13 2023-02-16 Inovio Pharmaceuticals Inc. Combination therapy to treat brain cancer
CN115887669A (zh) * 2022-12-19 2023-04-04 国纳之星(上海)纳米科技发展有限公司 一种治疗癌症的药物组合物
CN115869399B (zh) * 2022-12-28 2024-01-12 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用
CN121127264A (zh) * 2023-03-13 2025-12-12 瑞泽恩制药公司 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
CN122180519A (zh) * 2023-11-15 2026-06-09 瑞泽恩制药公司 用于增强在治疗肺癌中的功效的pd-1抑制剂和lag-3抑制剂的组合
AU2024391585A1 (en) * 2023-11-30 2026-06-04 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor
CN119607196A (zh) * 2023-12-13 2025-03-14 正大天晴药业集团股份有限公司 抗lag-3抗体与抗pd-1抗体的应用
WO2025237275A1 (zh) * 2024-05-13 2025-11-20 南京维立志博生物科技股份有限公司 用于治疗肿瘤的抗lag-3抗体或其抗原结合部分

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
JP3700859B2 (ja) 1994-05-06 2005-09-28 アンスティテュ ギュスタブ ルシ Lag−3タンパク質の可溶性ポリペプチドフラクション;製造方法、治療用製剤、抗イディオタイプ抗体
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
PT843557E (pt) 1995-07-21 2003-03-31 Applied Research Systems Metodos para detectar indentificar isolar e etiquetar e abordar selectivamente linfocitos th1 por intermedio da proteina lag-3
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
EP3848393A1 (en) * 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11390676B2 (en) 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
AU2018247916B2 (en) * 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3

Also Published As

Publication number Publication date
EA202192528A1 (ru) 2022-01-27
SG11202111262XA (en) 2021-11-29
ZA202107760B (en) 2026-04-29
IL287728A (en) 2021-12-01
BR112021021713A2 (pt) 2022-04-19
CL2021002966A1 (es) 2022-08-26
WO2020232019A1 (en) 2020-11-19
AU2020276242B2 (en) 2025-01-30
MX2021013815A (es) 2021-12-14
CA3136568A1 (en) 2020-11-19
JP2025065211A (ja) 2025-04-17
CN120939219A (zh) 2025-11-14
EP3969040A1 (en) 2022-03-23
US20220249659A1 (en) 2022-08-11
JP2022532490A (ja) 2022-07-15
MA55965A (fr) 2022-03-23
AU2020276242A1 (en) 2021-12-02
KR20220007593A (ko) 2022-01-18
NZ781933A (en) 2025-07-25
CN113825527A (zh) 2021-12-21

Similar Documents

Publication Publication Date Title
MX2021013815A (es) Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
FI4175951T3 (fi) Hpk1-estäjiä ja niiden käyttötapoja
MX2024009727A (es) Terapias de combinacion.
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
WO2019161221A3 (en) Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2018007756A (es) Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
EP4667493A3 (en) Lag-3 combination therapy for the treatment of cancer
WO2020092792A3 (en) Method of enhancing immune-based therapy
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
NZ589880A (en) Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate
CR20240296A (es) Inhibidores parp1
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
ZA201904432B (en) Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
NZ749997A (en) Combination of a pd-l antagonist and a raf inhibitor for treating cancer
PH12022552347A1 (en) Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2024000406A (es) Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
MX2025010672A (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para potenciar la eficacia en el tratamiento del melanoma.
EP4382168A3 (en) Intralesional administration of pd-1 inhibitors for treating skin cancer